KPTI · Karyopharm Therapeutics Inc. · Executive Compensation
$0.02
+0.00 (+3.45%)
At close · Nov 11
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$408,266
Shares
22.68M
Volume · Nov 11
8.28M
Avg daily vol (3M)
8.53M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | President and Chief Executive Officer | $2,320,902 |
| Reshma Rangwala | Chief Medical Officer and Head of Research | $2,016,134 |
| Stuart Poulton | Executive Vice President, Chief Development Officer | $1,399,580 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | President and Chief Executive Officer | $2,069,341 |
| Reshma Rangwala | Chief Medical Officer and Head of Research | $1,124,444 |
| Sohanya Cheng | Chief Commercial Officer and Head of Business Development | $1,094,829 |
| Stuart Poulton | Executive Vice President, Chief Development Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | President and Chief Executive Officer | $2,626,288 |
| Reshma Rangwala | Chief Medical Officer and Head of Research | $1,227,789 |
| Sohanya Cheng | Chief Commercial Officer and Head of Business Development | $1,193,414 |
| Michael Mason | Chief Financial Officer | $1,139,312 |
| Stuart Poulton | Chief Development Officer | $1,109,115 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | President and Chief Executive Officer | $6,910,015 |
| Sharon Shacham | Former Chief Scientific Officer | $6,037,789 |
| Michael Mason | Chief Financial Officer | $2,699,032 |
| Sohanya Cheng | Chief Commercial Officer | $2,612,718 |
| Ran Frenkel | Former Chief Development Officer | $2,160,250 |
| Michael Mano | General Counsel | $2,060,407 |
| Stuart Poulton | Chief Development Officer | $1,795,247 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | President and Chief Executive Officer | $8,355,172 |
| Sharon Shacham | Former Chief Scientific Officer | $3,106,591 |
| Michael Kauffman | M.D., Ph.D. | $3,069,589 |
| Michael Mason | Chief Financial Officer | $1,744,578 |
| Jatin Shah | Former Executive Vice President, Chief Medical Officer | $1,588,213 |
| Ran Frenkel | Former Chief Development Officer | $1,577,203 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Senior Clinical | Advisor and Former Chief Executive Officer | $3,937,039 |
| Michael Kauffman | M.D., Ph.D. Chief Executive Officer | $3,937,039 |
| Sharon Shacham | Former Chief Scientific Officer | $3,670,884 |
| Michael Mason | Chief Financial Officer | $2,266,816 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Senior Clinical | Advisor and Former Chief Executive Officer | $3,231,504 |
| Michael Kauffman | M.D., Ph.D. Chief Executive Officer | $3,231,504 |
| Sharon Shacham | Ph.D., M.B.A. Chief Scientific Officer and Former President | $3,020,459 |
| Christopher Primiano | J.D., M.B.A. Executive Vice President, Chief Business Officer, General Counsel and Secretary | $1,623,347 |
| Michael Mason | M.B.A., C.P.A. Executive Vice President, Chief Financial Officer and Treasurer | $956,697 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Michael Kauffman | M.D., Ph.D. Chief Executive Officer | $2,274,945 |
| Sharon Shacham | Ph.D., M.B.A. President and Chief Scientific Officer | $2,089,383 |
| Christopher Primiano | J.D., M.B.A. Executive Vice President, Chief Business Officer, General Counsel and Secretary | $1,522,593 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christy J. Oliger | Class I director | Appointed | 2026-05-28 |
| Barry E. Greene | Class I director | Appointed | 2026-05-28 |
|
Mansoor Raza Mirza, M.D.
“Dr. Mirza’s resignation is due to competing professional demands and not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2025-09-11 |
| Zhen Su, M.D., M.B.A. | Class III director | Appointed | 2025-05-29 |
| Garen G. Bohlin | Class III director | Appointed | 2025-05-29 |
| Lori Macomber | Executive Vice President, Chief Financial Officer and Treasurer | Appointed | 2025-01-02 |
| Kristin Abate | Vice President, Chief Accounting Officer, and Assistant Treasurer | Appointed | 2024-11-20 |
| Michael Mason | Executive Vice President, Chief Financial Officer and Treasurer | Resigned | 2024-08-29 |
| Chen Schor | Class II director | Appointed | 2024-05-31 |
| Richard Paulson | Class II director | Appointed | 2024-05-31 |
| Deepika R. Pakianathan | Class II director | Appointed | 2024-05-31 |
|
Peter K Honig, M.D., MPH
“Dr. Honig’s resignation is due to competing professional demands and not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2023-12-08 |
| Zhen Su, M.D., M.B.A | independent director | Appointed | 2023-09-01 |
| Christy J. Oliger | Class I director | Appointed | 2023-05-25 |
| Mansoor Raza Mirza M.D. | Class I director | Appointed | 2023-05-25 |
| Barry E. Greene | Class I director | Appointed | 2023-05-25 |
| Stuart Poulton | Executive Vice President, Chief Development Officer | Appointed | 2022-07-28 |
| Ran Frenkel | Executive Vice President, Chief Development Officer | Resigned | 2022-07-28 |
| Sharon Shacham, Ph.D., M.B.A. | observer to the Board | Resigned | 2022-03-29 |
| Michael G. Kauffman, M.D. Ph.D. | Board of Directors | Resigned | 2022-03-29 |
| Michael G. Kauffman, M.D., Ph.D. | Board of Directors | Resigned | 2022-03-28 |
| Peter K Honig, M.D., MPH | independent director | Appointed | 2021-12-06 |
| Mikael Dolsten | Board of Directors | Resigned | 2021-12-06 |
Leadership
- Richard Paulson CEO, Board Member
- Senior Clinical CEO
- Michael Mano General Counsel
- Kristin Abate Chief Accounting Officer
- Barry E. Greene Board Member
- Chen Schor Board Member
- Christy J Oliger Board Member
- Christy J. Oliger Board Member
- Deepika R. Pakianathan Board Member
- Garen G. Bohlin Board Member
- Mansoor Raza Mirza M.D. Board Member
- Peter Honig, M.D., M.P.H. Board Member
- Peter K Honig Board Member
- Peter K Honig, M.D., MPH Board Member
- Zhen Su Board Member
- Zhen Su, M.D., M.B.A Board Member
- Zhen Su, M.D., M.B.A. Board Member
Key facts
CIK
1503802
CUSIP
48576U205
13F (30d)
102 filings
86 filers
Visit website
Investor relations